CSL: Upgraded to an Add

Morgans Financial Limited

Morgans Financial Limited

Our FY18-20 NPAT estimates decline up to 1.6%, mainly on higher opex and interest expense. However, with >10% total shareholder return, we upgrade to an Add rating and continue to view CSL as a core holding. 

CSL Limited's FY17 underlying results came in above guidance, supported via solid core plasma sales, with margins up on higher value products and efficiencies.

Above-market growth in core Ig and Specialty segments, helped by 1H competitor stumbles, along with strong uptake of haemophilia B product Idelvion and an on-track turnaround Seqirus vaccine division, all underpinned the strength.

Despite second half weakness (as we expected) and FY18 looking like a reinvestment year (as we also expected), it appears more than captured in the outlook, which may ultimately prove conservative given CSL's market leading breadth, diversity and multiple new product launches.

 

 

Contributed by Derek Jellinek, Senior Analyst, Sectors Covered: Healthcare:  (VIEW LINK)

 


1 stock mentioned

Morgans Financial Limited
Morgans Financial Limited
Stockbroker
Morgans Financial Limited

Morgans is Australia's largest national full-service retail stockbroking and wealth management network with over 240,000 client accounts, 500 authorised representatives and 950 employees operating from offices in all states and territories.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment